NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis → This unknown company solves the biggest issue with AI (From Manward Press) (Ad) Free ARCT Stock Alerts $29.02 -0.72 (-2.42%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$28.87▼$30.6550-Day Range$25.57▼$38.6952-Week Range$17.52▼$43.81Volume293,131 shsAverage Volume461,823 shsMarket Capitalization$781.37 millionP/E RatioN/ADividend YieldN/APrice Target$64.86 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSocial Media Get Arcturus Therapeutics alerts: Email Address Arcturus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside123.6% Upside$64.86 Price TargetShort InterestBearish20.02% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.68Based on 20 Articles This WeekInsider TradingSelling Shares$910,434 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.39) to ($0.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.34 out of 5 starsMedical Sector533rd out of 928 stocksPharmaceutical Preparations Industry251st out of 431 stocks 3.5 Analyst's Opinion Consensus RatingArcturus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcturus Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Arcturus Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted20.02% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in Arcturus Therapeutics has recently increased by 6.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARCT. Previous Next 2.6 News and Social Media Coverage News SentimentArcturus Therapeutics has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Arcturus Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $910,434.00 in company stock.Percentage Held by Insiders13.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arcturus Therapeutics are expected to grow in the coming year, from ($4.39) to ($0.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -7.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Manward PressThis unknown company solves the biggest issue with AINvidia is the 800-lb gorilla in AI chips. But… it has a big problem. That's where one tiny company comes in. Discover why this company About Arcturus Therapeutics Stock (NASDAQ:ARCT)Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.Read More ARCT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARCT Stock News HeadlinesMay 15 at 4:01 PM | businesswire.comArcturus Therapeutics to Attend Upcoming Investor & Scientific ConferencesMay 14 at 5:06 AM | americanbankingnews.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Buy" from BrokeragesMay 12 at 9:16 AM | msn.comArcturus Therapeutics (NASDAQ:ARCT) Making Significant Strides Towards GrowthMay 12 at 4:30 AM | americanbankingnews.comCanaccord Genuity Group Lowers Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $86.00May 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus Therapeutics Amidst Strong Financial Outlook and Promising Clinical AdvancementsMay 9, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights:May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) (Q1 2024) Earnings Call Transcript Highlights: ...May 9, 2024 | finance.yahoo.comArcturus Therapeutics Holdings First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | investorplace.comARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | sfgate.comArcturus Therapeutics: Q1 Earnings SnapshotMay 8, 2024 | finance.yahoo.comArcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline ProgressApril 29, 2024 | finance.yahoo.comArcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five yearsApril 25, 2024 | businesswire.comArcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024April 23, 2024 | seekingalpha.comArcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic FibrosisApril 16, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and 23andMe Holding (ME)April 9, 2024 | markets.businessinsider.comAlnylam Pharma Earns Buy Rating on Robust Clinical Trials and Strategic PartnershipsApril 6, 2024 | cnn.comArcturus Therapeutics Holdings, Inc.April 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arcturus: Promising Vaccine Commercialization and Rare Disease Pipeline ProgressMarch 29, 2024 | finanznachrichten.deIntravacc B.V.: Intravacc and Primrose Bio Announce Partnership to Enhance Conjugate Vaccine DevelopmentMarch 28, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc (ARCT) Insider Sells SharesMarch 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Arcturus Therapeutics Amid Strong Kostaive Vaccine Market Prospects in JapanMarch 22, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Inc's Chief Scientific Officer & COO Pad Chivukula Sells ...March 17, 2024 | finance.yahoo.comArcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagSee More Headlines Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/15/2024Next Earnings (Estimated)8/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARCT CUSIPN/A CIK1410997 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees180Year FoundedN/APrice Target and Rating Average Stock Price Target$64.86 High Stock Price Target$90.00 Low Stock Price Target$45.00 Potential Upside/Downside+123.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,730,000.00 Net Margins-81.59% Pretax Margin-82.40% Return on Equity-37.61% Return on Assets-23.99% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$169.93 million Price / Sales4.60 Cash FlowN/A Price / Cash FlowN/A Book Value$9.80 per share Price / Book2.96Miscellaneous Outstanding Shares26,930,000Free Float23,215,000Market Cap$781.51 million OptionableOptionable Beta2.65 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Joseph E. Payne M.Sc. (Age 52)Founder, President, CEO & Director Comp: $1.13MDr. Padmanabh Chivukula Ph.D. (Age 45)Founder, Chief Scientific Officer, COO & Secretary Comp: $787.5kMr. Andrew H. Sassine MBA (Age 60)CFO & Director Comp: $826.88kMs. Neda SafarzadehVice President and Head of IR/PR & MarketingMr. Lance KurataChief Legal OfficerMs. Natash O. BowmanChief Human Resources OfficerMr. Kevin T. SkolChief Business OfficerDr. Juergen Froehlich FCPh (Age 68)M.D., MBA, Chief Medical Officer Dr. Igor Smolenov M.D.Ph.D., Chief Development OfficerJoseph RobertsControllerMore ExecutivesKey CompetitorsEvolusNASDAQ:EOLSLongboard PharmaceuticalsNASDAQ:LBPHALX OncologyNASDAQ:ALXOTango TherapeuticsNASDAQ:TNGXDisc MedicineNASDAQ:IRONView All CompetitorsInsiders & InstitutionsLazard Asset Management LLCSold 8,439 shares on 5/15/2024Ownership: 0.072%Price T Rowe Associates Inc. MDBought 922 shares on 5/15/2024Ownership: 0.063%Public Employees Retirement System of OhioBought 1,800 shares on 5/15/2024Ownership: 0.017%Shell Asset Management Co.Sold 3,094 shares on 5/14/2024Ownership: 0.051%CANADA LIFE ASSURANCE CoBought 428 shares on 5/14/2024Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions ARCT Stock Analysis - Frequently Asked Questions Should I buy or sell Arcturus Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ARCT shares. View ARCT analyst ratings or view top-rated stocks. What is Arcturus Therapeutics' stock price target for 2024? 7 brokers have issued 12 month price targets for Arcturus Therapeutics' stock. Their ARCT share price targets range from $45.00 to $90.00. On average, they expect the company's stock price to reach $64.86 in the next year. This suggests a possible upside of 123.6% from the stock's current price. View analysts price targets for ARCT or view top-rated stocks among Wall Street analysts. How have ARCT shares performed in 2024? Arcturus Therapeutics' stock was trading at $31.53 at the beginning of 2024. Since then, ARCT stock has decreased by 8.0% and is now trading at $29.01. View the best growth stocks for 2024 here. When is Arcturus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 5th 2024. View our ARCT earnings forecast. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) posted its earnings results on Thursday, March, 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($1.69) by $1.37. The biotechnology company had revenue of $33.99 million for the quarter, compared to the consensus estimate of $64.14 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative trailing twelve-month return on equity of 37.61%. What ETFs hold Arcturus Therapeutics' stock? ETFs with the largest weight of Arcturus Therapeutics (NASDAQ:ARCT) stock in their portfolio include Morningstar US Small Growth (MSGR), Subversive Mental Health ETF (SANE), ARK Genomic Revolution ETF (ARKG), Amplify Treatments, Testing and Advancements ETF (GERM), WisdomTree BioRevolution Fund (WDNA), AXS Green Alpha ETF (NXTE), Tema Cardiovascular and Metabolics ETF (HRTS) and Jacob Forward ETF (JFWD). What is Joe Payne's approval rating as Arcturus Therapeutics' CEO? 11 employees have rated Arcturus Therapeutics Chief Executive Officer Joe Payne on Glassdoor.com. Joe Payne has an approval rating of 90% among the company's employees. 70.0% of employees surveyed would recommend working at Arcturus Therapeutics to a friend. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and Who are Arcturus Therapeutics' major shareholders? Arcturus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.15%), Sumitomo Mitsui Trust Holdings Inc. (4.74%), Nikko Asset Management Americas Inc. (4.74%), Nordea Investment Management AB (0.21%), Assenagon Asset Management S.A. (0.21%) and Hennion & Walsh Asset Management Inc. (0.12%). Insiders that own company stock include Keith C Kummerfeld, Magda Marquet, Pad Chivukula and Ultragenyx Pharmaceutical Inc. View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARCT) was last updated on 5/15/2024 by MarketBeat.com Staff From Our PartnersElon’s New Device is About to Shock the WorldInvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsWith revenue forecasted to grow dramatically in 2024 and beyond, this company should be on your radarStocks NewsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap Sniper Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
